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ABSTRACT
Nasal drug delivery has received a great deal of attention as a convenient, reliable, and promising method for the systemic administration of drugs. 
It is especially for those molecules which are ineffective orally and only effective if administered by injection. The nasal route of drug delivery has 
advantages over the other alternative systems of non-invasive drug administration. The present review describes nasal delivery systems in recognizing 
to its potential and limits. The present review is an attempt to provide some information concerning nasal drug delivery system such as limitations, 
advantages, mechanism of drug absorption, anatomy of nasal cavity, factors affecting of nasal drug delivery, strategies to enhance nasal absorption, 
strategies to extend duration of drug formulations within the nasal cavity, leading to improved nasal drug absorption, novel drug formulations, sorts 
of nasal drug delivery system with uses of nasal drug delivery in various diseases, and recent advancement of nasal delivery systems.
Keywords: Nasal drug delivery systems, Non-invasive drug administration, Anatomy and physiology, Recent advancement.
INTRODUCTION
In recent time, the nasal drug delivery received a great deal of 
attention for its convenient, promising, and reliable way of systemic 
administration for drugs, especially for those drugs which are 
ineffective orally and those which must be administered by injections. 
This route provides a large surface area, porous endothelial 
membrane, high total blood flow, bypassing the first-pass metabolism, 
and ready accessibility. Furthermore, nasal mucosa is permeable to 
more compounds than the gastrointestinal tract due to the absence 
of pancreatic, gastric enzymatic activities, and interference by 
gastrointestinal contents. The early recorded historical application 
of nasal drug delivery was restricted to topical applications of drugs 
intended for only local effects. However in recent times, its application 
grown to include a wide range of targeted areas in the body to produce 
local and systemic effects. Nasal drug delivery also finds a special place 
in the traditional system of medicine such as the Ayurvedic system 
of Indian medicine which is called as “Nasya karma” and is a well-
recognized way of treatment [1-4].
In therapeutics, nose forms an important part of the body for 
faster and higher level of drug absorption with the possibility of 
self-administration. Drugs are ranging from small micromolecules 
to large macromolecules such as peptide/proteins, hormones, 
and vaccines, are being delivered through the nasal cavity. It is 
reported that lipophilic drugs are generally well absorbed from the 
nasal cavity with pharmacokinetic profiles often identical to those 
obtained following an intravenous injection with a bioavailability 
approaching up to 100% in many cases. Large absorption surface 
area and high vascularization lead to fast absorption. In emergency, 
nasal route can be used as a substitute route of parenteral 
administration [5-8]. Drugs are rapidly absorbed from the nasal 
cavity after intranasal administration, resulting in rapid systemic 
drug absorption. An approach if made for increasing the residence 
time of drug formulations in the nasal cavity can result in improved 
nasal drug absorption. Depending on the desired site of drug 
action, the drug to be inhaled needs to be adjusted to particle size, 
concentration, and chemical form to ensure a local or systemic drug 
action.
POSSIBILITIES FOR THE USE OF THE NASAL CAVITY FOR DRUG 
DELIVERY
The easy accessibility and available surface area make the nose a possibly 
viable drug delivery organ. Pharmaceutical product development is an 
essential task which is directly dependent on its therapeutic objectives. 
The aspects to be considered for product development depend on 
whether it is intended for:
a) Local delivery
b) Systemic delivery
c) Single or repetitive administration.
Local delivery
Nasal delivery is a logical delivery choice for local (or topical) treatment 
as it provides the minimal potential for systemic adverse effects when 
compared to the oral route of administration, and hence, relatively low 
doses are effective when administered through nasal route with less 
systemic toxic effects. Prominent therapeutic classes of drugs delivered 
are decongestants for cold nasal symptoms and antihistamines and 
corticosteroids for allergic rhinitis [9,10].
Systemic delivery
The intranasal administration of drugs is an effective way for the 
systemic availability of drugs as compared to oral and intravascular 
routes of administration. It provided fast and extended drug absorption 
than oral and parenteral administration. Therapeutic classes of drugs 
delivered include analgesics (exmorphine), cardiovascular drugs 
as propranolol and carvedilol, hormones such as levonorgestrel, 
progesterone, and insulin, anti-inflammatory agents as indomethacin 
and ketorolac, and antiviral drugs (acyclovir). Some examples which are 
available in the market include zolmitriptan and sumatriptan for the 
treatment of a migraine and cluster headaches [9, 11-15].
Nasal vaccines
During inhalation nasal mucosa is the first site of contact with 
inhaled antigens, and therefore, its use for vaccination, especially for 
respiratory infections, has been extensively evaluated. In fact, nasal 
vaccination is a promising alternative to the classic parenteral route 
because it can enhance the systemic levels of specific immunoglobulin 
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G and nasal secretory immunoglobulin A. Examples of the human 
efficacy of intranasal vaccines include those against influenza A and B 
virus, proteosoma-influenza, adenovirus-vectored influenza, Group B 
meningococcal native, attenuated respiratory syncytial virus, and 
parainfluenza 3 virus [9, 16-19].
CENTRAL NERVOUS SYSTEM (CNS) DELIVERY THROUGH NASAL 
ROUTE
The intranasal route has encouraging approach for the delivery of drugs 
to the brain. The delivery of drugs to CNS from the nasal route may 
occur through olfactory neuroepithelium. Drug delivery through nasal 
route into CNS has been reported for Alzheimer’s disease, brain tumors, 
epilepsy, pain, and sleep disorders [20,21,22,23].
ANATOMICAL AND PHYSIOLOGICAL CONSIDERATION FOR 
INTRANASAL DELIVERY
Anatomy
The human skull is composed of two active sections for  protecting the 
delicate structures within it. One of them, is the neurocranium which 
surrounds and protects the brain while the other, viscerocranium 
composed of several bones that form the skeleton of the face as well 
as parts of the jaw offering protection to eyes, mouth and the nasal 
cavity [24,25]. Nasal cavity can anatomically be segregated into five 
different regions: The nasal vestibule, atrium, respiratory area, olfactory 
region, and the nasopharynx Table 1. The nasal cavity is divided into two 
symmetrical halves by the nasal septum (comprised bone and cartilage), 
each cavity has volume up to approximately 7.5 mL and a surface area 
around 75 cm2. The nasal cavity extends posteriorly to the nasopharynx. 
The most anterior part of the nasal cavity, the nasal vestibule opens 
at the face through the nostrils. The atrium is an intermediate region 
between the vestibule and the respiratory region. The respiratory 
region occupies the major part of the nasal cavity which possesses 
lateral walls dividing it into three sections: Inferior (C1), middle (C2), 
and superior (C4) nasal turbinates. These folds provide the nasal cavity 
with a very high surface area of about 150 cm2 in humans compared to 
its small volume. The respiratory region is richly supplied with blood, 
and receives the maximum amount of nasal secretions, rendering it 
most suitable for the permeation of compounds. The olfactory region 
situated above the superior nasal turbinate which possesses ciliated 
olfactory nerve cells for smell perception. The total surface area of the 
olfactory epithelium is about 200–400 mm2 [24,26,27,28].
The systemic circulation using nasal drug delivery was as follows:
1.	 Hepatic	first-pass	metabolism	is	avoided.
2. Improving patient compliance compared to parenteral routes as easy 
accessibility and needle-free drug application without the presence 
of trained personnel facilitates self-medication.
3. Drug degradation that is observed in the gastrointestinal tract can 
be bypass.
4. Using absorption enhancer, the bioavailability of large drug molecules 
can be improved through nasal route.
5. Rapid drug absorption and quick onset of action can be achieved 
easily.
6. Bioavailability though nasal route for smaller drug molecules is good.
7.	 Drug	possessing	poor	stability	in	GIT	fluids	is	given	by	nasal	route.
8. Studies reveal that the nasal route is an alternate to parenteral route, 
especially, for protein and peptide drugs.
9. A polar compound exhibiting poor oral absorption may be 
particularly suited for this route of delivery.
10. Convenient for the patients, especially for those on long-term therapy, 
when compared with parenteral medication.
Disadvantages [29-31]
1. The nasal cavity provides a smaller absorption surface area when 
compared to gastrointestinal tract.
2. There is a possibility of irritation when compared to the oral delivery 
system since.
3. The substance and constituents added to the dosage form may cause 
local side effects and irreversible damage of the cilia on the nasal 
mucosa.
4. There could be a mechanical loss of the dosage form into the other 
parts of the respiratory tract like lungs due to the improper technique 
of administration.
5. Certain surfactants used as chemical enhancers may disrupt and 
even dissolve the membrane in high concentration.
Limitations of nasal drug delivery [32,29-31,33]
1. There is a risk of both of irreversible damage of the cilia of the nasal 
mucosa and local side effects from both constituents and substances 
additional to the dosage form.
2. There can be a mechanical loss of the dosage form in other parts of 
the respiratory system, for example, lungs due to the inappropriate 
technique of administration.
3. Some of the surfactants used as a chemical catalyst and may cause 
or even dissolve the membrane at high concentrations.
Advantages of nasal drug delivery [32,29-31,33,34,35]
•	 Drugs	that	are	orally	not	absorbed	can	be	delivered	to	volume	that	
can be delivered into nasal cavity are restricted to 25–200 µL
1. High-molecular-weight compounds cannot be delivered  
through this route (mass cut off ~1 kDa).
2. Adversely affected by pathological conditions.
Table 1: Structural features of various regions and their impact on the permeability of nasal cavity
Region Structural features Permeability
Nasal vestibule Nasal hairs (vibrissae)
Epithelial cells are stratified, squamous, and keratinized
Sebaceous glands present
Least permeable due to the presence of 
keratinized cells, very resistant to hydration 
and can withstand insults from noxious 
substances of the environment
Atrium Transepithelial region
Stratified squamous cells present anteriorly and 
pseudostratified cells with microvilli present posteriorly
The narrowest region of the nasal cavity
Less permeable as it has small surface area and 
stratified cells are present anteriorly
Respiratory region (inferior 
turbinate middle turbinate 
superior turbinate)
Pseudostratified ciliated columnar cells with microvilli (300 per 
cell), large surface area
Receives maximum nasal secretions due to the presence of 
seromucous glands, nasolacrimal duct, and goblet cells
Richly supplied with blood for heating and humidification of 
inspired air, the presence of paranasal sinuses
Most permeable region due to large surface 
area and rich vasculature
Olfactory region Specialized ciliated olfactory nerve cells for smell perception
Receives ophthalmic and maxillary divisions of the trigeminal 
nerve
Direct access to cerebrospinal fluid
Nasopharynx The upper part contains ciliated cells, and the lower part 
contains squamous epithelium
Receives nasal cavity drainage
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3. Large interspecies variability is observed in this route.
4. Normal defense mechanisms such as mucociliary clearance and 
ciliary beating affect the permeability of the drug.
5. The enzymatic barrier to the permeability of drugs.
6. Irritation of nasal mucosa by drugs.
7. Limited understanding of mechanisms and less developed 
models at this stage.
8. Enhanced patient compliances.
9. Decrease risk of overdose.
10. Fast onset of therapeutic action. Factor affecting nasal drug 
absorption. The rate and extent of nasal absorption of a drug 
are dependent on various factors listed in Table 2. The factors 
that	can	influence	drug	absorption	from	the	nasal	cavity	are	very	
important in designing both formulation and the device used for 
intranasal administration [36,37,38,39].
MECHANISM OF NASAL DRUG ABSORPTION
Two mechanisms have been considered predominantly out of several 
mechanisms that have been proposed.
The first involves an aqueous route of transport, which is also known as 
the paracellular route. Key feature of this mechanism involves
•	 This	route	is	slow	and	passive.
•	 There	is	an	inverse	log-log	correlation	between	intranasal	absorption	
and the molecular weight of water-soluble compounds.
•	 Poor	bioavailability	was	observed	for	a	drug	with	a	molecular	weight	
greater than 1000 Daltons
The second involves transport through a lipoidal route is also known 
as the transcellular process and is responsible for the transport of 
lipophilic drugs that show a rate dependency on their lipophilicity. For 
examples, chitosan, a natural biopolymer from shellfish, opens tight 
junctions between epithelial cells to facilitate drug transport [40,41,42].
STRATEGIES FOR IMPROVING DRUG AVAILABILITY IN NASAL 
DELIVERY
Various strategies used to improve the availability of the drug in the 
nasal mucosa include:
1. Nasal residence time improvement
2. Nasal absorption enhancement
3.	 Modification	 of	 drug	 structure	 to	 change	 its	 physicochemical	
properties [43,44,45].
To improve the nasal residence time
Mucociliary clearance acts to remove the foreign bodies and substances 
from nasal mucosa as quickly as possible. One way of delaying clearance 
is to apply the drug to the anterior part of the nasal cavity, an effect that 
is largely determined by the type of dosage form used. The preparation 
could also be formulated with polymers such as methylcellulose, 
hydroxy propyl methyl cellulose or polyacrylic acid also with Various 
compounds used as an enhancer in nasal drug delivery research of 
nasal drug delivery systems listed in Table 3, in which incorporation 
ofthe polymer increases the viscosity of the formulation and also 
acts as a bio-adhesive with mucus.Increase in residence time does 
not necessarily lead to an increase the absorption; this concept can 
be illustrated by considering insulin solution with similar viscosity 
containing carbopol and carboxymethylcellulose (CMC). Here, carbopol 
enhances the absorption, whereas CMC solution does not enhance 
the absorption of insulin. If we increase the viscosity, slow diffusion 
of the drug from matrix causes retention in absorption with CMC. In 
case of carbopol causes enhancement of absorption due to opening 
the intracellular junctions. One more lucrative way to increase the 
nasal resistance time is using biodegradable microspheres as a carrier 
for drug delivery. Biodegradable microspheres swell in the presence 
of water, thereby increasing the viscosity. This phenomenon leads to 
increase the nasal residential time.
Enhancing nasal absorption
It is possible to greatly improve the nasal absorption of polar drugs 
by administering them in combination within an absorption enhancer 
that promotes the transport of the drug across the nasal membrane. 
Furthermore, a nasal drug delivery system that combines an absorption 
enhancing activity with a bioadhesive effect, which increases the 
residence time of the formulation in the nasal cavity, has been shown 
to be even more effective for improving the nasal absorption of polar 
drugs. A wide range of absorption enhancer systems has been evaluated 
in animal models (and some in man). Certainly, in animal models, they 
have been shown to improve significantly the nasal absorption of 
drugs. Animal models, such as the rabbit and even the dog, can give 
Table 2: Factors influencing intranasal drug delivery
Biological factors Formulation-related factors Strategies to overcome them
Biochemical changes
Refer to the enzymatic barrier of nasal mucus
Which include oxidative and conjugative
Enzymes, peptidases, and proteases
Physiological factors
Blood supply and neuronal regulation
Nasal secretions
Nasal cycle
pH of the nasal cavity














Partition coefficient and pKa
Solubility and dissolution rate
Physicochemical properties of formulation




Area of nasal membrane exposed
Area of solution applied
Dosage form
The physical form of the formulation







Specialized systems, for example, microspheres, 
liposomes, etc.
Prodrugs
Enzyme inhibitors Absorption 
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leading results, most probably a result of the different architecture 
and morphology of the nasal cavity and also the use of anesthetics 
or sedating procedures that can affect the mucociliary clearance 
mechanism [46,47,48]. As an example, some years ago [49,50,51-53] 
published results from a study on the nasal delivery of insulin using 
the	rat	model	with	dimethyl-β-cyclodextrin	as	the	absorption	enhancer.	
They obtained an astonishing bioavailability of 100% when compared 
with a subcutaneous injection of insulin. Later, when the same 
formulation was tested in rabbits and man, the resulting bioavailability 
in both animal species was almost 0%. Second, enhancers, such 
as surfactants, bile salts, fatty acids, and most phospholipids and 
lysophospholipids, can work by modifying the phospholipid bilayer 
structure of cells, leaching out proteins or even stripping off the 
outer layer of the mucosa, thereby promoting the observed improved 
transcellular transport of drugs. In general, for such enhancer systems, 
there is a direct correlation between the bioavailability obtained and 
damage caused to the membrane [54,55,56]. For other enhancers, 
especially those that work by transiently opening the tight junctions 
between the cells (e.g., chitosan, see later) and selected cyclodextrins 
and phospholipids, the absorption enhancing effect can greatly outweigh 
any modifications caused to the mucosa. The absorption enhancement 
mechanisms can be grouped into two classes: Physicochemical effects: 
Some enhancers can alter the physicochemical properties of a drug in 
the formulation. This can happen by altering the drug solubility, drug 
partition coefficient, or by weak ionic interactions with the drug and 
membrane effects: Many enhancers show their effects by affecting the 
nasal mucosa surface [29,42].
Modifying drug structure
Modification of drug structure without altering pharmacological 
activity is one of the lucrative ways to improve the nasal absorption. 
Here, a modification of physiochemical properties such as molecular 
size, molecular weight, pKa, and solubility is favorable for nasal drug 
absorption [21,55-58].
Designing of nasal formulation depends on the therapeutic need of the 
particular drug molecule, duration of action, and duration of therapy. 
Both controlled release and conventional release drug delivery are 
possible through nasal route. The requirement of the pharmaceutical 
excipients depends on the mode of drug delivery, that is, local or 
systemic drug delivery [59-63]. A wide range of nasal formulations 
are available and many studies have been done so far, some of these 
delivery systems and their key features are summarized below.
Nasal drops
They are the most convenient and simple system developed for nasal 
drug delivery. Nose drops can be delivered with a squeezy or by a pipette 
a bottle. These pharmaceuticals formulations are often recommended 
for treating local conditions, which include suffering some challenges 
such as microbial growth, mucosal dysfunction, and non-specific loss 
of the nose or lower back [61-66]. The featured disadvantage of this 
system is the lack of the dose precision, and therefore, nasal drops may 
not be useful for prescription products. It has been reported that nasal 
drops deposit human serum albumin in the nostrils more efficiently 
than nasal sprays.
Nasal sprays
Solution and suspension are formulated into nasal sprays. Availability 
of metered dose pumps and actuators, a nasal spray can deliver an 
exact	 dose	 from	 25	 to	 200	 μm.	 The	 morphology	 particles	 size	 (for	
suspensions) of the drug and viscosity of the formulation determine the 
choice of pump and actuator assembly [61,62,65,67].
Nasal gels
Until the recent development of precise dosing device, there was 
not a lot of interest during this system. Nasal gels are high viscosity 
thickened solutions or suspensions. The benefits of a nasal gel include 
the reduction of post-nasal drip due to high viscosity, reduction of 
taste impact due to reduced swallowing, reduction of anterior leakage 
of the formulation, reduction of irritation using soothing/emollient 
excipients, and target to mucosa for higher absorption [61,65,67,68,23].
Nasal powder
This dosage form may be formulated if solution and suspension dosage 
forms cannot be formulated, for example, due to lack of drug stability. 
The advantages to the nasal powder dosage form are the absence of 
superior stability and preservative of the formulation. However, the 
suitability of the powder formulation is dependent on the solubility, 
particles size, aerodynamic properties, and nasal irritancy of the active 
drug and excipients. Local application of the drug is another advantage 
of this system [35,39, 61,65,67,70].
Liposomes
These are phospholipid vesicles composed by bilayer enclosing one 
or more aqueous compartments, in these compartments drug can be 
entrapped or adsorbed.
Microspheres
Microsphere has an important role in nasal drug delivery with 
enhancing absorption, sustained release, and also has great importance 
because it protects the drug from enzymatic degradation [34].
EVALUATION OF NASAL FORMULATIONS
To improving the efficiency and effectiveness of active principles, 
formulations, and devices, another important objective of the 
pharmaceutical research is improving the link between in vitro test 
data and in vivo performance. In this way, the helpful dialogue among 
manufacturing, regulators, and academic investigators, which already 
started with workshops concerning bioequivalence, is continuing. 
These formal attitudes are most likely to reflect those involved in the 
development of oral or nasal inhalation orally inhaled and nasal drug 
products, and this reflex is often given special attention to their design 
and analytical control [34,69,70].
In vitro nasal permeation studies
Various methods are used to determine the drug diffusion through 
nasal mucosa from the formulation.
The two most important ways to study the diffusion profile of the drug 
are discussed below.
In vitro diffusion studies
The nasal diffusion cell is fabricated in the glass. The water-jacketed 
recipient chamber has a total capacity of 60 ml and a flanged top of 
about 3 mm; the lid has three opening, each for sampling, thermometer, 
and a donor tube chamber. The 10 cm long donor chamber and a donor 
Table 3: Various compounds used as an enhancer in nasal drug 
delivery research of nasal drug delivery systems
Name of compound Example
Surfactants SDS, polyoxyethylene-9-laurylether, 
phosphatidylcholines
Complexing and chelating 
agents
EDTA
Cyclodextrins and derivatives α-, β-, γ-cyclodextrin, DMβ-, 
HPβ-cyclodextrin
Fusidic acid derivative STDHF
Bile salts Sodium taurocholate, sodium 
glycocholate
Dry microspheres Degradable starch microsphere, 
dextran microspheres
SDS: Sodium dodecyl sulfate, EDTA: Ethylenediaminetetraacetic acid, 
STDHF: Sodium tauradihydrofusidate
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tube chamber has a total capacity of 60 ml and a flanged top of about 
3 mm; the lid has three openings, each for sampling, thermometer, and 
a donor tube chamber. The 10 cm long donor chamber tube has an 
internal diameter of 1.13 cm. The nasal mucosa of sheep was separated 
from sublayer bony tissues and stoned in distilled water containing few 
drops at gentamicin injection. After the complete removal of blood from 
mucosal surface, is attached to the donor chamber tube. The donor 
chamber tube is placed such a way that it just touches the diffusion 
medium in recipient chamber. At predetermined intervals, samples 
(0.5 ml) from recipient chamber are with a draw and transferred to 
amber colored ampoules. The samples withdrawn are suitably replaced. 
The samples are estimated for drug content by a suitable analytical 
technique. Throughout the experiment, the temperature is maintained 
at 37°C [61,69-71], in vitro, one study showed that almost 95.2% drug 
was released from the formulation within 2 min [72].
In vivo nasal absorption studies
Animal models for nasal absorption studies
The animal models employed for nasal absorption studies can be of 
two types, namely whole animal or in vivo model and isolated organ 
perfusion or ex vivo model.
In vivo models are rat model, rabbit model, monkey model, and dog 
model [62,70,73,74].
Ex vivo nasal perfusion models
Surgical preparation is that the same as that is for in vivo rat model. 
During the perfusion studies, a funnel is placed between the nose and 
reservoir to minimize the loss of the drug solution. The drug solution is 
placed in a reservoir maintained at 37°C and is circulated through the 
nasal cavity of the rat with a peristaltic pump. The perfusion solution 
passes out from the nostrils (through the funnel) and runs once more 
into the reservoir. The drug solution within the reservoir is continuously 
stirred. The amount of drug absorbed is estimated by measuring the 
residual drug concentration within the perfusing solution. The drug 
activity due to stability problems may be lost during experiment. This 
is especially true for peptide and protein drugs that may undergo 
proteolysis and aggregation. Rabbit may be used as the animal model 
for ex vivo nasal perfusion studies. The rabbit is anesthetized with 
parenteral urethane-acepromazine. A midline incision is made in 
the neck, and the trachea is cannulated with a polyethylene neonatal 
endotracheal tube. The esophagus is isolated and ligated. The distal 
end of the esophagus is closed with suture, and flexible Tygon tubing 
is inserted into the proximal end and advanced to the posterior part of 
the nasal cavity. The nasopalatine tract (that connects the nasal cavity 
to the mouth) is closed with an adhesive to avoid drainage of drug 
solution from the nasal cavity. The drug in the isotonic buffer solution is 
recirculated using a peristaltic pump [62,60,70,75-77].
CONCLUSION
The nasal cavity has a large surface area and a highly vascularized 
mucosa. Drugs absorbed by the rich network of blood vessels pass 
directly into the systemic circulation, thereby avoiding the first-
pass metabolism. A growing body of evidence relating to nasal drug 
delivery suggests it might use for challenging drugs which can facilitate 
the pharmaceutical manufacturing and drug delivery challenges. 
Considering the wealth of activity and interest in the area of nasal 
drug delivery, together with the potential benefits from this route of 
administration, we should expect to see a range of novel nasal products 
reaching the market shortly.
Future needs and further research and development
It is not surprising to find a lot of research focusing to develop nasal 
drug delivery system and its contribution in therapeutic management. 
In general, a concise overview of the pharmacotherapy of nasal drug 
delivery system has highlighted that in spite of the availability of new 
drugs and several specialized devices.
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